Measuring unmet medical need to inform R&D decisions

A drug’s value is determined by how much it reduces unmet medical need. The greater the reduction in need, the greater the value to society and the higher the commercial return to the developer. Equinox Group measures unmet medical need and the impact that a new drug has on it. We do this using objective data taken from the peer-reviewed literature, and analyze that information with a rigorous and consistent method. The results of this analysis provide unique insights to inform decisions at all phases of R&D.

Informing R&D Decisions
Assessing the potential value of a new drug program during the early stages of R&D vastly reduces wasted time and budget, because it cuts the risk of developing programs with low commercial potential. The cost to estimate the potential value of a program is insignificant compared with the cost of development. So estimating value should be one of the earliest “experiments” to assess the merits of a program. Furthermore, as the understanding of a drug’s clinical attributes evolves, the updated data can be quickly analyzed in our framework to inform both the decision to advance the program and the choice of patient segments to pursue.

Please call or email us about your need to assess unmet medical need. We welcome the chance to discuss the challenges you face.Walter Brooks
Vice President
Equinox Group
1-781-676-2054walter.brooks@equinox-group.com